Antisense and antigene oligonucleotides: Structure, stability and delivery

Biomaterials for Delivery and Targeting of Proteins and Nucleic Acids

Volumn , Issue , 2004, Pages 569-600

  Mahato, Ram I ^a   Ye, Zhaoyang ^a   Guntaka, Ramareddy V ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84855250749     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (114)

1. Zamecnik, P. C., and Stephenson, M. L., Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA, 1978; 75: 280-284.
2. Opalinska, J. B., and Gewirtz, A. M., Nucleic-acid therapeutics: basic principles and recent applications. Nat. Rev. Drug Discov., 2002; 1: 503-514.
3. Crooke, S. T., Vitravene—another piece in the mosaic. Antisense Nucleic Acid Drug Dev., 1998; 8: 7-8.
4. Guntaka, R. V., Varma, B. R., and Weber, K. T., Triplex-forming oligonucleotides as modulators of gene expression. Int. J. Biochem. Cell Biol., 2003; 35: 22-31.
5. Seidman, M. M., and Glazer, P. M., The potential for gene repair via triple helix formation. J. Clin. Invest., 2003; 112: 487-494.
6. Vasquez, K. M., and Glazer, P. M., Triplex-forming oligonucleotides: principles and applications. Q. Rev. Biophys., 2002; 35: 89-107.
7. Lee, M. et al., Repression of GAD autoantigen expression in pancreas betaCells by delivery of antisense plasmid/PEG-g-PLL complex. Mol. Ther., 2001; 4: 339-346.
8. Long, M. B., Jones, J. P. 3rd, Sullenger B. A., and Byun, J., Ribozyme-mediated revision of RNA and DNA. J. Clin. Invest., 2003; 112: 312-318.
9. Wall, N. R., and Shi, Y., Small RNA: can RNA interference be exploited for therapy? Lancet, 2003; 362: 1401-1403.
10. Mahato, R. I., Takakura, Y., and Hashida, M., Development of targeted delivery systems for nucleic acid drugs. J. Drug Target, 1997; 4: 337-357.
11. Wickstrom, E., Oligodeoxynucleotide stability in subcellular extracts and culture media. J. Biochem. Biophys. Methods, 1986; 13: 97-102.
12. Micklefield, J., Backbone modification of nucleic acids: synthesis, structure and therapeutic applications. Curr. Med. Chem., 2001; 8: 1157-1179.
13. Kurreck, J., Antisense technologies. Improvement through novel chemical modifications. Eur. J. Biochem., 2003; 270: 1628-1644.
14. Akhtar, S., and Juliano, R. L., Cellular uptake and intracellular fate of antisense oligonucleotides. Trends Cell Biol., 1992; 2: 139-144.
15. Hu, Q., Bally, M. B., and Madden, T. D., Subcellular trafficking of antisense oligonucleotides and down-regulation of bcl-2 gene expression in human melanoma cells using a fusogenic liposome delivery system. Nucleic Acids Res., 2002; 30: 3632-3641.
16. Bulmus, V. et al., A new pH-responsive and glutathione-reactive, endo-somal membrane-disruptive polymeric carrier for intracellular delivery of biomolecular drugs. J. Control Release, 2003; 93: 105-120.
17. Alahari, S. K. et al., Inhibition of expression of the multidrug resistance-associated P-glycoprotein of by phosphorothioate and 5' cholesterol-conjugated phosphorothioate antisense oligonucleotides. Mol. Pharmacol., 1996; 50: 808-819.
18. Jensen, K. D., Kopeckova, P., and Kopecek, J., Antisense oligonucleotides delivered to the lysosome escape and actively inhibit the hepatitis B virus. Bioconjug. Chem., 2002; 13: 975-984.
19. Nori, A. et al., Tat-conjugated synthetic macromolecules facilitate cytoplasmic drug delivery to human ovarian carcinoma cells. Bioconjug. Chem., 2003; 14: 44-50.
20. Moulton, H. M., Hase, M. C., Smith, K. M., and Iversen, P. L., HIV Tat peptide enhances cellular delivery of antisense morpholino oligomers. Antisense Nucleic Acid Drug Dev., 2003; 13: 31-43.
21. Eckstein, F., Phosphorothioate oligodeoxynucleotides: what is their origin and what is unique about them? Antisense Nucleic Acid Drug Dev., 2000; 10: 117-121.
22. Campbell, J. M., Bacon, T. A., and Wickstrom, E., Oligodeoxynucleoside phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid. J. Biochem. Biophys. Methods, 1990; 20: 259-267.
23. Thierry, A. R. et al., Cellular uptake and intracellular fate of antisense oligonucleotides. Curr. Opin. Mol. Ther., 2003; 5: 133-138.
24. Crooke, S. T., Progress in antisense technology: the end of the beginning. Methods Enzymol., 2000; 313: 3-45.
25. Tonkinson, J. L., and Stein, C. A., Antisense oligodeoxynucleotides as clinical therapeutic agents. Cancer. Invest., 1996; 14: 54-65.
26. Krieg, A. M., and Stein, C. A., Phosphorothioate oligodeoxynucleotides: antisense or anti-protein? Antisense Res. Dev., 1995; 5: 241.
27. Galbraith, W. M. et al., Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res. Dev., 1994; 4: 201-206.
28. Crooke, S. T., and Bennett, C. F., Progress in antisense oligonucleotide therapeutics. Annu. Rev. Pharmacol. Toxicol., 1996; 36: 107-129.
29. Sarmiento, U. M., Perez, J. R., Becker, J. M., and Narayanan, R., In vivo toxicological effects of rel A antisense phosphorothioates in CD-1 mice. Antisense Res. Dev., 1994; 4: 99-107.
30. Agrawal, S., and Kandimalla, E. R., Antisense therapeutics: is it as simple as complementary base recognition? Mol. Med. Today, 2000; 6: 72-81.
31. Rusckowski, M., Qu, T., Roskey, A., and Agrawal, S., Biodistribution and metabolism of a mixed backbone oligonucleotide (GEM 231) following single and multiple dose administration in mice. Antisense Nucleic Acid Drug Dev., 2000; 10: 333-345.
32. Agrawal, S. et al., Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies. Proc. Natl. Acad. Sci. USA, 1997; 94: 2620-2625.
33. Heidenreich, O., Gryaznov, S., and Nerenberg, M., RNase H-independent antisense activity of oligonucleotide N3'!P5' phosphoramidates. Nucleic Acids Res, 1997; 25: 776-780.
34. Skorski, T. et al., Antileukemia effect of c-myc N3'!P5' phosphoramidate antisense oligonucleotides in vivo. Proc. Natl. Acad. Sci. USA, 1997; 94: 3966-3971.
35. Gryaznov, S. M. et al., Oligonucleotide N3'!P5' phosphoramidates. Proc. Natl. Acad. Sci. USA, 1995; 92: 5798-5802.
36. Verma, S., and Eckstein, F., Modified oligonucleotides: synthesis and strategy for users. Annu. Rev. Biochem., 1998; 67: 99-134.
37. Engels, J. W., and Uhlmann, E., Chemistry of oligonucleotides. In: Couvreur, P., and Malvy, C. (eds), Pharmaceutical Aspects of Oligonucleotides. Taylor & Francis: London, 2000, pp. 35-68.
38. Summerton, J., and Weller, D., Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev., 1997; 7: 187-195.
39. Hudziak, R. M. et al., Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense Nucleic Acid Drug Dev., 1996; 6: 267-272.
40. Summerton, J. et al., Morpholino and phosphorothioate antisense oligomers compared in cell-free and in-cell systems. Antisense Nucleic Acid Drug Dev., 1997; 7: 63-70.
41. Taylor, M. F., Paulauskis, J. D., Weller, D. D., and Kobzik, L., In vitro efficacy of morpholino-modified antisense oligomers directed against tumor necrosis factor-alpha mRNA. J. Biol. Chem., 1996; 271: 17445-17452.
42. Stein, D. A., Skilling, D. E., Iversen, P. L., and Smith, A. W., Inhibition of Vesivirus infections in mammalian tissue culture with antisense morpholino oligomers. Antisense Nucleic Acid Drug Dev., 2001; 11: 317-325.
43. Arora, V., and Iversen, P. L., Redirection of drug metabolism using antisense technology. Curr. Opin. Mol. Ther., 2001; 3: 249-257.
44. Arora, V., Cate, M. L., Ghosh, C., and Iversen, P. L., Phosphorodiamidate morpholino antisense oligomers inhibit expression of human cytochrome P450 3A4 and alter selected drug metabolism. Drug Metab. Dispos., 2002; 30: 757-762.
45. Vikram, A., Derek, C. K., Muralimohan, T. R., Dwight, D. W., and Patrick, L. I., Bioavailability and efficiency of antisense morpholino oligomers targeted to c-myc and cytochrome P450 3A2 following oral administration in rats. J. Pharmaceut. Sci., 2002; 91: 1009-1018.
46. McCaffrey, A. P. et al., A potent and specific morpholino antisense inhibitor of hepatitis C translation in mice. Hepatology, 2003; 38: 503-508.
47. Dagle, J. M., and Weeks, D. L., Oligonucleotide-based strategies to reduce gene expression. Differentiation, 2001; 69: 75-82.
48. Furdon, P. J., Dominski, Z., and Kole, R., RNase H cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothio-ate and phosphodiester bonds. Nucleic Acids Res., 1989; 17: 9193-9204.
49. Dash, P. et al., Selective elimination of mRNAs in vivo: complementary oligodeoxynucleotides promote RNA degradation by an RNase H-like activity. Proc. Natl. Acad. Sci. USA, 1987; 84: 7896-7900.
50. Walder, R. Y., and Walder, J. A., Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc. Natl. Acad. Sci. USA, 1988; 85: 5011-5015.
51. Dagle, J. M., Weeks, D. L., and Walder, J. A., Pathways of degradation and mechanism of action of antisense oligonucleotides in Xenopus laevis embryos. Antisense Res. Dev., 1991; 1: 11-20.
52. Krieg, A. M., Immune effects and mechanisms of action of CpG motifs. Vaccine, 2000; 19: 618-622.
53. Scheule, R. K., The role of CpG motifs in immunostimulation and gene therapy. Adv. Drug Deliv. Rev., 2000; 44: 119-134.
54. Krieg, A. M. et al., CpG motifs in bacterial DNA trigger direct B-cell activation. Nature, 1995; 374: 546-549.
55. Payette, P. J., Davis, H. L., and Krieg, A. M., Role of CpG motifs in immuno-stimulation and gene expression. In: Mahato RIaK, S. W. (ed.). Pharmaceutical Perspectives of Nucleic Acid-Based Therapeutics. Taylor & Francis: London, 2002, pp. 467-486.
56. Kandimalla, E. R. et al., A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif. Proc. Natl. Acad. Sci. USA, 2003; 100: 14303-14308.
57. Dove, A., Antisense and sensibility. Nat. Biotechnol., 2002; 20: 121-124.
58. Lonsdorf, A. S. et al., Intratumor CpG-oligodeoxynucleotide injection induces protective antitumor T cell immunity. J. Immunol., 2003; 171: 3941-3946.
59. Dalpke, A., Zimmermann, S., and Heeg, K., Immunopharmacology of CpG DNA. Biol. Chem, 2002; 383: 1491-1500.
60. Agrawal, S., and Kandimalla, E. R., Medicinal chemistry and therapeutic potential of CpG DNA. Trends Mol. Med., 2002; 8: 114-121.
61. Praseuth, D., Guieysse, A. L., and Helene, C., Triple helix formation and the antigene strategy for sequence-specific control of gene expression. Biochim. Biophys. Acta., 1999; 1489: 181-206.
62. Maher, L. J. 3rd, Prospects for the therapeutic use of antigene oligonucleotides. Cancer Invest., 1996; 14: 66-82.
63. Potaman, V. N., Applications of triple-stranded nucleic acid structures to DNA purification, detection and analysis. Expert Rev. Mol. Diagn., 2003; 3: 481-496.
64. Gewirtz, A. M., Sokol, D. L., and Ratajczak, M. Z., Nucleic acid therapeutics: state of the art and future prospects. Blood, 1998; 92: 712-736.
65. Olivas, W. M., and Maher, L. J. 3rd. Competitive triplex/quadruplex equilibria involving guanine-rich oligonucleotides. Biochemistry, 1995; 34: 278-284.
66. Faruqi, A. F., Krawczyk, S. H., Matteucci, M. D., and Glazer, P. M., Potassium-resistant triple helix formation and improved intracellular gene targeting by oligodeoxyribonucleotides containing 7-deazaxanthine. Nucleic Acids Res., 1997; 25: 633-640.
67. Ferdous, A., Watanabe, H., Akaike, T., and Maruyama, A., Poly(L-lysine)-graft-dextran copolymer: amazing effects on triplex stabilization under physiological pH and ionic conditions (in vitro). Nucleic Acids Res., 1998; 26: 3949-3954.
68. Maruyama, A. et al., Characterization of interpolyelectrolyte complexes between double-stranded DNA and polylysine comb-type copolymers having hydrophilic side chains. Bioconjug. Chem., 1998; 9: 292-299.
69. Ferdous, A., Akaike, T., and Maruyama, A., Mechanism of intermolecular purine-purine-pyrimidine triple helix stabilization by comb-type polylysine graft copolymer at physiologic potassium concentration. Bioconjug. Chem., 2000; 11: 520-526.
70. Majumdar, A. et al., Targeted gene knockout mediated by triple helix forming oligonucleotides. Nat. Genet., 1998; 20: 212-214.
71. Faria, M. et al., Targeted inhibition of transcription elongation in cells mediated by triplex-forming oligonucleotides. Proc. Natl. Acad. Sci. USA, 2000; 97: 3862-3867.
72. Sawai, K. et al., Disposition of oligonucleotides in isolated perfused rat kidney: involvement of scavenger receptors in their renal uptake. J. Pharmacol. Exp. Ther, 1996; 279: 284-290.
73. Yoshida, M. et al., Disposition characteristics of plasmid DNA in the singlepass rat liver perfusion system. Pharm. Res., 1996; 13: 599-603.
74. Takakura, Y. et al., Uptake characteristics of oligonucleotides in the isolated rat liver perfusion system. Antisense Nucleic Acid Drug Dev., 1996; 6: 177-183.
75. Takakura, Y., and Hashida, M., Macromolecular carrier systems for targeted drug delivery: pharmacokinetic considerations on biodistribution. Pharm. Res., 1996; 13: 820-831.
76. Takakura, Y., Mahato, R. I., and Hashida, M., Control of pharmacokinetic profiles of drug-macromolecule conjugates. Adv. Drug Del. Rev., 1996; 19: 377.
77. Brown, M. S. et al., The scavenger cell pathway for lipoprotein degradation: specificity of the binding site that mediates the uptake of negatively-charged LDL by macrophages. J. Supramol. Struct., 1980; 13: 67-81.
78. Acton, S. et al., The collagenous domains of macrophage scavenger receptors and complement component C1q mediate their similar, but not identical, binding specificities for polyanionic ligands. J. Biol. Chem., 1993; 208: 3530-3537.
79. Inagaki, M. et al., Antisense oligonucleotides: inhibition of liver cell proliferation and in vivo disposition. Transplant Proc., 1992; 24: 2971-2972.
80. Bijsterbosch, M. K. et al., In vivo fate of phosphorothioate antisense oligo-deoxynucleotides: predominant uptake by scavenger receptors on endothelial liver cells. Nucleic Acids Res., 1997; 2S: 3290-3296.
81. Rappaport, J. et al., Transport of phosphorothioate oligonucleotides in kidney: implications for molecular therapy. Kidney. Int., 1995; 47: 1462-1469.
82. Geary, RS. et al., Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression. Drug Metab. Dispos, 1997; 2S: 1272-1281.
83. Geary, R. S. et al., Pharmacokinetic properties in animals. In: Crooke, S. T. (ed.), Antisense Drug Technology. Marcel Dekker, Inc.: New York, 2001, pp. 119-154.
84. DeLong, R. K. et al., Comparative pharmacokinetics, tissue distribution, and tumor accumulation of phosphorothioate, phosphorodithioate, and methylphosphonate oligonucleotides in nude mice. Antisense Nucleic Acid Drug Dev, 1997; 7: 71-77.
85. Yakubov, L. A. et al., Mechanism of oligonucleotide uptake by cells: involvement of specific receptors? Proc. Natl. Acad. Sci. USA, 1989; 86: 6454-6458.
86. Crooke, S. T., Progress in antisense technology. Annu. Rev. Med., 2004; 55: 61-95.
87. Loke, S. L. et al., Characterization of oligonucleotide transport into living cells. Proc. Natl. Acad. Sci. USA, 1989; 86: 3474-3478.
88. Wu-Pong, S., Bard, J., Huffman, J., and Jimerson, J., Oligonucleotide biological activity: relationship to the cell cycle and nuclear transport. Biol. Cell, 1997; 89: 257-261.
89. Shoji, Y. et al., Mechanism of cellular uptake of modified oligodeoxy-nucleotides containing methylphosphonate linkages. Nucleic Acids. Res., 1991; 19: 5543-5550.
90. Akhtar, S., Basu, S., Wickstrom, E., and Juliano, R. L., Interactions of antisense DNA oligonucleotide analogs with phospholipid membranes (liposomes). Nucleic Acids Res., 1991; 19: 5551-5559.
91. Stuart, D. D., and Allen, T. M., A new liposomal formulation for antisense oligodeoxynucleotides with small size, high incorporation efficiency and good stability. Biochim. Biophys. Acta., 2000; 1463: 219-229.
92. Bennett, C. F. et al., Structural requirements for cationic lipid mediated phosphorothioate oligonucleotides delivery to cells in culture. J. Drug Target, 1998; 5: 149-162.
93. Zelphati, O., Szoka, F. C., Jr. Mechanism of oligonucleotide release from cationic liposomes. Proc. Natl. Acad. Sci. USA, 1996; 93: 11493-11498.
94. Schlepper-Schafer, J. et al., Endocytosis via galactose receptors in vivo. Ligand size directs uptake by hepatocytes and/or liver macrophages. Exp. Cell Res., 1986; 165: 494-506.
95. Kawabata, K., Takakura, Y., and Hashida, M., The fate of plasmid DNA after intravenous injection in mice: involvement of scavenger receptors in its hepatic uptake. Pharm. Res., 1995; 12: 825-830.
96. Mahato, R. I. et al., Physicochemical and disposition characteristics of antisense oligonucleotides complexed with glycosylated poly(L-lysine). Biochem. Pharmacol., 1997; 53: 887-895.
97. Rajur, S. B., Roth, C. M., Morgan, J. R., and Yarmush, M. L., Covalent protein-oligonucleotide conjugates for efficient delivery of antisense molecules. Bioconjug. Chem., 1997; 8: 935-940.
98. Maier, M. A. et al., Synthesis of antisense oligonucleotides conjugated to a multivalent carbohydrate cluster for cellular targeting. Bioconjug. Chem., 2003; 14: 18-29.
99. Washio, K. et al., The effect of epidermal growth factor receptor antisense morpholino oligomer on non-small cell lung cancer cell line. Oncol. Rep., 2003; 10: 1967-1971.
100. Crooke, S. T. et al., Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J. Pharmacol. Exp. Ther., 1996; 277: 923-937.
101. Bijsterbosch, M. K. et al., bis-Cholesteryl-conjugated phosphorothioate oligodeoxynucleotides are highly selectively taken up by the liver. J. Pharmacol. Exp. Ther., 2002; 302: 619-626.
102. Manoharan, M., Oligonucleotide conjugates in antisense technology. In: Crooke, S. T. (ed.). Antisense Drug Technology. Marcel Dekker, New York, 2001, pp. 391-469.
103. Bijsterbosch, M. K. et al., Delivery of cholesteryl-conjugated phosphorothioate oligodeoxynucleotides to Kupffer cells by lactosylated low-density lipoprotein. Biochem. Pharmacol., 2001; 62: 627-633.
104. Desjardins, J. et al., Cholesteryl-conjugated phosphorothioate oligodeoxy-nucleotides modulate CYP2B1 expression in vivo. J. Drug Target, 1995; 2: 477-485.
105. Epa, W. R. et al., Enhanced downregulation of the p75 nerve growth factor receptor by cholesteryl and bis-cholesteryl antisense oligonucleotides. Antisense Nucleic Acid Drug Dev., 1998; 8: 489-498.
106. LeDoan, T. et al., Cell binding, uptake and cytosolic partition of HIV anti-gag phosphodiester oligonucleotides 3'-linked to cholesterol derivatives in macrophages. Bioorg. Med. Chem., 1999; 7: 2263-2269.
107. Gryaznov, S. M., and Lloyd, D. H., Modulation of oligonucleotide duplex and triplex stability via hydrophobic interactions. Nucleic Acids Res., 1993; 21: 5909-5915.
108. Li, S., Deshmukh, H. M., and Huang, L., Folate-mediated targeting of antisense oligodeoxynucleotides to ovarian cancer cells. Pharm. Res., 1998; 15: 1540-1545.
109. Bonora, G. M. et al., Synthesis and characterization of high-molecular mass polyethylene glycol-conjugated oligonucleotides. Bioconjug. Chem., 1997; 8: 793-797.
110. Graham, M. J. et al., In vivo distribution and metabolism of a phosphoro-thioate oligonucleotide within rat liver after intravenous administration. J. Pharmacol. Exp. Ther., 1998; 286: 447-458.
111. Hangeland, J. J., Levis, J. T., Lee, Y. C., and Ts’o, P. O., Cell-type specific and ligand specific enhancement of cellular uptake of oligodeoxy-nucleoside methylphosphonates covalently linked with a neoglycopeptide, YEE(ah-GalNAc)3. Bioconjug Chem., 1995; 6: 695-701.
112. Duff, R. J. et al., Intrabody tissue-specific delivery of antisense conjugates in animals: ligand-linker-antisense oligomer conjugates. Methods Enzymol., 2000; 313: 297-321.
113. Biessen, E. A. et al., Targeted delivery of oligodeoxynucleotides to parenchymal liver cells in vivo. Biochem. J., 1999; 340 (Pt 3): 783-792.
114. Biessen, E. A. et al., Targeted delivery of antisense oligonucleotides to parenchymal liver cells in vivo. Methods Enzymol., 2000; 314: 324-342.